Connection

Carl Atkinson to Mice, Inbred BALB C

This is a "connection" page, showing publications Carl Atkinson has written about Mice, Inbred BALB C.
Connection Strength

1.190
  1. In Situ Pre-Treatment of Vascularized Composite Allografts With a Targeted Complement Inhibitor Protects Against Brain Death and Ischemia Reperfusion Induced Injuries. Front Immunol. 2021; 12:630581.
    View in: PubMed
    Score: 0.172
  2. Emphysema-associated Autoreactive Antibodies Exacerbate Post-Lung Transplant Ischemia-Reperfusion Injury. Am J Respir Cell Mol Biol. 2019 06; 60(6):678-686.
    View in: PubMed
    Score: 0.148
  3. C3a receptor antagonism as a novel therapeutic target for chronic rhinosinusitis. Mucosal Immunol. 2018 09; 11(5):1375-1385.
    View in: PubMed
    Score: 0.138
  4. Donor pretreatment with nebulized complement C3a receptor antagonist mitigates brain-death induced immunological injury post-lung transplant. Am J Transplant. 2018 10; 18(10):2417-2428.
    View in: PubMed
    Score: 0.137
  5. A simplified cuff technique for abdominal aortic transplantation in mice. J Surg Res. 2016 Feb; 200(2):707-13.
    View in: PubMed
    Score: 0.114
  6. Targeting pathogenic postischemic self-recognition by natural IgM to protect against posttransplantation cardiac reperfusion injury. Circulation. 2015 Mar 31; 131(13):1171-80.
    View in: PubMed
    Score: 0.110
  7. Donor brain death exacerbates complement-dependent ischemia/reperfusion injury in transplanted hearts. Circulation. 2013 Mar 26; 127(12):1290-9.
    View in: PubMed
    Score: 0.096
  8. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest. 2005 Sep; 115(9):2444-53.
    View in: PubMed
    Score: 0.057
  9. Modulating donor mitochondrial fusion/fission delivers immunoprotective effects in cardiac transplantation. Am J Transplant. 2022 02; 22(2):386-401.
    View in: PubMed
    Score: 0.044
  10. Increasing the efficacy and safety of a human complement inhibitor for treating post-transplant cardiac ischemia reperfusion injury by targeting to a graft-specific neoepitope. J Heart Lung Transplant. 2021 10; 40(10):1112-1121.
    View in: PubMed
    Score: 0.043
  11. Complement C3a and C5a receptors promote GVHD by suppressing mitophagy in recipient dendritic cells. JCI Insight. 2018 12 20; 3(24).
    View in: PubMed
    Score: 0.036
  12. Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy. Transplantation. 2017 04; 101(4):e75-e85.
    View in: PubMed
    Score: 0.032
  13. Targeting complement component 5a promotes vascular integrity and limits airway remodeling. Proc Natl Acad Sci U S A. 2013 Apr 09; 110(15):6061-6.
    View in: PubMed
    Score: 0.024
  14. CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Circ Res. 2011 Nov 11; 109(11):1290-301.
    View in: PubMed
    Score: 0.022
  15. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol. 2008 Dec 01; 181(11):8068-76.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.